CERO — CERO THERAPEUTICS HOLDINGS, INC.
—
OTC ·
Health Care ·
Biotechnology ·
CIK 1870404 ·
Last close
$0.01
Market Cap
$608.9K
52W High
$4.40
52W Low
$0.01
ADV30
644,735
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,846,466 | -1,028,830 | 1,899,971 | 937,512 | 32,405,268 |
| Mar 2026 | 0 | — | -4,845,728 | -5,885,914 | 2,205,110 | 857,489 | 11,463,865 |
| Dec 2025 | 0 | — | -4,426,248 | -4,540,621 | 3,641,134 | 1,662,380 | 9,087,596 |
| Sep 2025 | 0 | — | -4,362,579 | -4,856,395 | 3,911,394 | 2,022,072 | 8,454,556 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-14,395,640
Investing CF
$0
Financing CF
$9,549,592
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-102.83
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-96,724,029
Inventory
—
Receivables
—
ST Investments
$500,000
EBIT TTM
$-19,939,546
Pretax Income TTM
$-20,700,245
Interest Exp TTM
$166,286
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -19,326,699 | -19,920,262 | 3,641,134 | 9,087,596 | -5,446,462 | -16,080,250 |
| Dec 2024 | — | — | — | 6,206,929 | 8,101,492 | -1,894,563 | — |
| Dec 2023 | 0 | -7,675,049 | -7,289,577 | 5,126,302 | 47,183,997 | -42,057,695 | -5,789,987 |
| Dec 2022 | 0 | -11,971,231 | -11,829,116 | 11,300,000 | 46,200,000 | -34,870,780 | -11,709,311 |
| Dec 2021 | 0 | -11,616,331 | -10,629,620 | — | — | — | -10,094,380 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
$-20,700,245
OpCashFlow TTM
—
Assets (Latest)
$2,205,110
Forward EPS
$-3.26
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SCNI | Scinai Immunotherapeutics Ltd. | $799.5K | $1.18 | — |
| AGTX | Agentix Corp. | $801.3K | $0.02 | — |
| CPMV | Mosaic ImmunoEngineering Inc. | $456.3K | $0.06 | — |
| SLXN | Silexion Therapeutics Corp | $1.19M | $0.21 | — |
| CRIS | CURIS INC | $1.63M | $0.67 | — |
News headlines (Yahoo Finance, 1h cache)
SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancie
2026-10-07 19:00 · Yahoo
SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers
2026-08-31 11:30 · Yahoo
Delisting of Securities from The Nasdaq Stock Market
2026-07-10 16:00 · Yahoo
CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial
2026-03-30 12:15 · Yahoo
CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment
2026-06-15 12:15 · Yahoo
CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial
2026-04-14 12:15 · Yahoo
CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial
2026-05-11 12:15 · Yahoo
CERo Therapeutics Provides Shareholder Update
2026-03-11 12:15 · Yahoo
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
2026-02-17 13:00 · Yahoo
CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient
2026-02-04 14:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.